Nguyen Le

Ms. Nguyen Le

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
NLNguyen Le
Nguyen Le
ATAnh Thi Tram Tu
Anh Thi Tram Tu
DZDandan Zhao
Dandan Zhao
CYChiaki Yoshikawa
Chiaki Yoshikawa
Kohsaku KawakamiKohsaku Kawakami
Kohsaku Kawakami
Tomohiko YAMAZAKITomohiko YAMAZAKI
Tomohiko YAMAZAKI
Cationic liposomes, specifically 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) liposomes, serve as successful carriers for guanine-quadruplex (G4) structure-based cytosine-guanine oligodeoxynucleotides (CpG ODNs). The combined benefits of CpG ODNs forming a G4 structure and a non-viral vector carrier endow the ensuing complex with promising adjuvant properties. Although G4-CpG ODN-DOTAP complexes show a higher immunostimulatory effect than naked G4-CpG ODNs, the effects of the complex composition, especially charge ratios, on the production of the pro-inflammatory cytokines interleukin (IL)-6 and interferon (IFN)-α remain unclear. Here, we examined whether charge ratios drive the bifurcation of cytokine inductions in human peripheral blood mononuclear cells. Linear CpG ODN-DOTAP liposome complexes formed micrometer-sized positively charged agglomerates; G4-CpG ODN-DOTAP liposome complexes with low charge ratios (0.5 and 1.5) formed ~250 nm-sized negatively charged complexes. Notably, low-charge-ratio (0.5 and 1.5) complexes induced significantly higher IL-6 and IFN-α levels simultaneously than high-charge-ratio (2 and 2.5) complexes. Moreover, confocal microscopy indicated a positive correlation between the cellular uptake of the complex and amount of cytokine induced. The observed effects of charge ratios on complex size, surface charge, and affinity for factors that modify cellular-uptake, intracellular-activity, and cytokine-production efficiency highlight the importance of a rational complex design for delivering and controlling G4-CpG ODN activity.

13 December 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
DZDandan Zhao
Dandan Zhao
ATAnh Thi Tram Tu
Anh Thi Tram Tu
MSMiwako Shobo
Miwako Shobo
NLNguyen Le
Nguyen Le
CYChiaki Yoshikawa
Chiaki Yoshikawa
Tomohiko YAMAZAKITomohiko YAMAZAKI
Tomohiko YAMAZAKI
Unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides (CpG ODNs) induce inflammatory cytokines and type I interferons (IFNs) to activate the immune system. To apply CpG ODNs as vaccine adjuvants, the cellular uptake and stability of phosphodiester-based, non-modified ODNs require further improvement. Previously developed new CpG ODNs forming guanine-quadruplex (G4) structures showed higher nuclease resistance and cellular uptake than linear CpG ODNs; however, the complex formation of G4-CpG ODNs with antigen proteins is necessary for their application as vaccine adjuvants. In this study, we utilized a cationic polymer, ε-poly-L-lysine (ε-PLL), as a carrier for G4-CpG ODNs and antigen. The ε-PLL/G4-CpG ODN complex exhibited enhanced stability against nucleases. Cellular uptake of the ε-PLL/G4-CpG ODN complex positively correlated with the N/P ratio. In comparison to naked G4-CpG ODNs, the ε-PLL/G4-CpG ODN complex induced extremely high levels of interleukin (IL)-6, IL-12, and IFN-β. Relative immune cytokine production was successfully tuned by N/P ratio modification. Mice with the ε-PLL/G4-CpG ODN/ovalbumin (OVA) complex showed increased OVA-specific immunoglobulin (Ig)G, IgG1, and IgG2c levels, whereas total IgE levels did not increase and weight gain rates were not affected. Therefore, ε-PLL can serve as a safe and effective phosphodiester-based, non-modified CpG ODN delivery system, and the ε-PLL/G4-CpG ODN/antigen complex is a highly promising candidate for vaccine adjuvants and can be further used in clinical research.

10 January 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
SPSoumitra Pathak
Soumitra Pathak
NLNguyen Le
Nguyen Le
TOTaiji Oyama
Taiji Oyama
YOYusuke Odahara
Yusuke Odahara
AMAtsuya Momotake
Atsuya Momotake
Tomohiko YAMAZAKITomohiko YAMAZAKI
Tomohiko YAMAZAKI
Synthetic cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODNs) are promising candidates for vaccine adjuvants, because they activate immune responses through the Toll-like receptor 9 (TLR9) pathway. However, unmodified CpG ODNs are quickly degraded by serum nucleases, and their negative charge hinders cellular uptake, limiting their clinical application. Our group previously reported that guanine-quadruplex (G4)-forming CpG ODNs exhibit enhanced stability and cellular uptake. G4 structures can form in parallel, anti-parallel, or hybrid topologies, depending on strand orientation, but the effects of these topologies on CpG ODNs have not yet been explored. In this study, we designed three distinct G4 topologies as scaffolds for CpG ODNs. Among the three topology, the parallel G4 CpG ODN demonstrated the highest serum stability and cellular uptake, resulting in the strongest immune response from macrophage cells. Additionally, we investigated the binding affinities of the different G4 topologies to macrophage scavenger receptor-1 and TLR9, both of which are key to immune activation. These findings provide valuable insights into the development of CpG ODN-based vaccine adjuvants.

17 June 2025 in bioRxiv
Verified
Preprint
Open access
MKMao Kinoshita
Mao Kinoshita
KKKen Kawaguchi
Ken Kawaguchi
NLNguyen Le
Nguyen Le
AKAtsushi Kainuma
Atsushi Kainuma
Teiji SawaTeiji Sawa
Teiji Sawa
SUSatoshi Uchida
Satoshi Uchida
With the growing threat of antimicrobial resistance (AMR), alternatives to antibiotics are urgently needed. In this study, we developed mRNA-based therapeutics encoding single-chain variable fragment (scFv) antibodies that target the type III secretion system of Pseudomonas aeruginosa , a key AMR pathogen. Delivered intravenously via lipid nanoparticles, the scFv mRNA effectively protected mice from airway infections by mitigating lung inflammation, reducing bacterial load, and improving survival. Notably, this approach proved effective in clinically relevant models involving immunocompromised mice infected with multidrug-resistant, exoU -positive (highly cytotoxic) clinical isolates. The study also explores the potential of Fc-free scFv formulations, leveraging mRNA technology to overcome their short half-life through sustained protein production. Importantly, Fc-free scFv antibodies migrated more efficiently from the bloodstream to the airway epithelium—the primary site of infection—than their Fc-conjugated counterparts, resulting in efficient therapeutic outcomes. Overall, mRNA-encoded Fc-free scFv antibodies represent a promising strategy for combating AMR infections.